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Background: Further evidence is needed on the effects that short- and long-term exposure 
to secondhand smoke (SHS) have on the respiratory health of patients with lung disease. 
Within the TackSHS project we aimed to assess the acute respiratory effects in lung 
function that result from short-term SHS exposure among patients with asthma and 
chronic obstructive pulmonary disease (COPD). 
Methods: The study design was an intervention trial with measurements before/after 
exposure to SHS in legal outdoor smoking areas. We studied patients with asthma or 
COPD from Czechia, Ireland, and Spain. Forced spirometry, peak flow and carbon 
monoxide (CO) measurements were performed pre- and 24 hours post- exposure.  
Results: Overall, 60 patients were studied, 30 with asthma, and 30 with COPD; 35 
(58.3%) were female. There were no significant differences observed in exhaled CO 
between pre- and 24 hours post-exposure neither in women (p =0.210), nor in men 
(p=0.169).  
A statistically significant decrease in forced vital capacity (FVC) was seen, overall, in 
asthma participants (p=0.02) and in forced expiratory volume in the first second (FEV1), 
(p=0.02), FVC (p=0.04) and peak expiratory flow rate (PEFR) (p=0.04) in female 
asthmatic participants. The observed decreases in respiratory measurements in COPD 
were not significant. There were no reported increases in symptoms, respiratory 
medication, or use of health services 24 hours after the exposure. 
Conclusion: We conclude that acute, short-term SHS exposure had a statistically 
significant effect on spirometry in female asthma patients but did not significantly modify 
spirometric indices 24 hours later in COPD patients.  
 







Research produced in the past three decades has provided substantial evidence of the 
harm that short and long-term exposure to secondhand smoke (SHS) represents to 
respiratory and cardiovascular health of adults and children. 1,2,3,4,5 
 
While interest in SHS exposure prevalence and its effects is increasing, 6,7 important gaps 
in evidence remain, and should be considered when designing national and international 
health policies aiming to protect those with lung disease.8 One of these gaps is a scarcity 
of studies objectively measuring markers of SHS in settings where smoking is not 
regulated, such as private places and outdoor public places.  
 
In many European countries, the introduction of smoke-free laws has prompted the 
proliferation of outdoor areas where smoking is permitted, and there exist places where 
non-smokers are still exposed to some levels of SHS. The possible health effects of such 
exposures are unknown. We are not aware of any studies in patients in such smoking 
areas. Some effects can be expected, given the known irritant effects of SHS or some of 
the constituents of SHS9, but it may be difficult to demonstrate any short-term measurable 
effects especially for ethical considerations unless in uncontrolled, real-life conditions. 
 
The project “Tackling secondhand tobacco smoke and e-cigarette emissions: exposure 
assessment, novel interventions, impact on lung diseases and economic burden in diverse 
European populations” (the TackSHS project) www.tackshs.eu was developed to address 
these and other challenges in the research of SHS and second-hand e-cigarette aerosols 
(SHA) from electronic cigarettes. TackSHS aims to comprehensively elucidate the impact 
that SHS and SHA have on the European population and how health impacts vary 
according to socioeconomic and other demographic characteristics, with a particular 
emphasis on specific vulnerable groups.10  
 
Asthma and chronic obstructive pulmonary disease (COPD) are the two most frequent 
chronic respiratory diseases;11 although all respiratory patients should refrain from 




This paper aims to assess if the acute effects in lung function that result from short-term 
SHS exposure among patients with stable doctor-diagnosed asthma and COPD. 
Methods 
The current study, led by TobaccoFree Research Institute Ireland (TFRI) is part of the 
TackSHS project10 and was conducted in Liberia (Czechia), Dublin (Ireland) and Madrid 
(Spain).  The study design was an intervention trial with measurements before/after 
exposure to SHS.  The study research protocol received ethical approval in each country 
and is registered at clinicaltrials.gov with identifier NCT03074734. All participants 
signed a written informed consent form.  
 
Participants 
Inclusion criteria for asthma patients were: confirmed doctor-diagnosed asthma, aged 18 
years and older, fully ambulatory, and crucially only patients with a history of frequent 
visits to smoking outdoor areas were included. Consequently more asthmatic smokers 
volunteered than may be representative of many asthmatic populations. The asthma 
patients were known to the referring physicians and regarded as stable with a mean 
asthma control test score (ACT) of 21.8 (SD 3.6). Inclusion criteria for COPD patients 
were: confirmed doctor-diagnosed COPD patients with confirmed airflow limitation by 
post-bronchodilator spirometry with FEV1/FVC < 0.7, aged 50 to 70 years old, current- 
or ex-smokers, fully ambulatory, and again with a history of frequent visits to smoking 
outdoor areas, clinically stable and a mean COPD Assessment Test (CAT) score of 11.6 
(SD 7.6). Exclusion criteria for both asthma and COPD patients were: under 18 years old, 
on oxygen therapy, never smokers in COPD patient group, undergoing treatment for acute 
exacerbations, pregnant women and patients not giving a history of visits to outdoor 
smoking areas of pubs.(Table 1). 
 
 
This study involved 60 patients (30 asthma and 30 COPD patients) in Czechia (30 
patients), Ireland (10 patients), and Spain (20 patients) between April 2018 and April 
2019. All participants were administered a validated symptoms questionnaire. The COPD 
Assessment Test (CAT) for all COPD patients,13 and  the Asthma Control Test (ACT) for 
all asthmatic patients,14 pre- and post-peak flow, spirometry, and CO measurements were 
carried out by the study researchers in each country.They were advised to take their usual 
 
 5 





An outdoor smoking area was defined in Irish law as: ‘a place or premises, or part of a 
place or premises that, is fully uncovered by any roof, fixed or mobile, or a place or 
premises that is covered by a roof, so long as not more than 50% of the perimeter (outside) 
is covered by a wall, windows, gate or similar’. 
 
The intervention was exposure to SHS in outside smoking areas. Study subjects were 
asked to spend at least 15 minutes in the outdoor smoking area, with a preferable time of 
30-60 mins.  They recorded time of entry to the outside area and duration of exposure. 
They also noted the characteristics of the area including the number of walls and the type 
of roof or canopy and the number of smokers present in the area.  
 
Outcome measures included pulmonary function changes in terms of forced spirometry 
and peak flow measurement pre- and post-exposure to SHS within 24 hours. Spirometry 
guidelines from the American Thoracic Society (ATS)/European Respiratory Society 
(ERS) Task Force were used15, which suggests that three acceptable manoeuvres should 
be achieved. The best two measurements must fulfil the reproducibility criteria. For 
FEV1 and FVC, the best two values should be within 5% or 150 mL of each other, 
whichever is greater. If FVC is <1.0 L, then the values should be within 100 ml. All 
spirometers used had valid calibration certificates. These measurements are the standard 
ones done in each of the three venues and the patients and researchers are familiar with 
the equipment and manoeuvres and serial stored data were available for comparison.  
The patients completed a questionnaire pre-exposure to SHS, which included items on 
respiratory medication, symptoms, and previous visits to emergency room or hospital 
admissions. Any significant variation from this was noted at the post exposure 








Data is presented as mean and standard deviation (SD) for continuous variables, or 
percentage for qualitative variables, as appropriate, and their 95% confidence interval 
(CI). Differences within groups were compared with Chi2 tests for categorical variables 
and Student t test or Wilcoxon test for continuous variables. A p value lower than 0.05 




Overall, 61 patients were recruited; three had to have their recording repeated due to 
equipment failure and one Irish COPD patient was not repeated. Therefore, 60 patients 
were finally studied (Figure 1), with a 98.4% response rate; 30 with asthma, and 30 with 
COPD, of whom 35 (58.3%) were female. Those with asthma were 19 (63.3%) female 
with a mean (SD) age of 46.9 (18.7) years, with 26.7% current smokers; while those with 
COPD were 16 (53.3%) female with age of 63.3 (10.2) years, with 70.0% current smokers 
(Table 1). Seven (23.3%) patients with asthma and 10 (33.3%) patients with COPD were 
living with a smoker. Most COPD patients had symptomatic, active disease as per their 
CAT 11.6 (7.5) score, while most asthma patients had their asthma controlled as per their 
ACT 21.8 (3.6). When in the outside areas, most participants (83.3%) were not exposed 
to aerosols of electronic cigarettes (data not shown in the tables). 
There were no significant differences in severity of disease by sex in asthma (p=0.813) 
or in COPD (p=0.770) scores (Table 2).  
Pulmonary function 
There was a small but statistically significant reduction in FVC, in asthmatic patients 
(p=0.02) (Table 3). In female asthmatic patients, however, there were statistically 
significant changes in (FVC) p=0.04, (FEV1) p=0.02 and (PEFR) p=0.04 but not in 
males. 
There were no statistically significant changes in pulmonary function tests in COPD in 
either sex but respiratory parameters were numerically lower post exposure (Table 3) 
Exhaled breath Carbon Monoxide parts per million (CO ppm):  
The CO in smokers was 10.21 (SD 10.03) ppm, and 1.47 (SD 1.22) ppm, in non-smokers 








The TackSHS project involves a comprehensive and innovative approach to enhance 
scientific understanding of SHS in chronic lung respiratory diseases. At the societal level, 
we aim to raise awareness of the risks from SHS and the health burden that SHS exposure 
presents. Our study explored the perceived effects on breathing in patients with asthma 
and COPD and measured changes in spirometry and peak flow in these respiratory 
patients after exposure to SHS in outside areas.  
Our main findings were that short-term SHS exposure did not result in any significant 
change in symptoms or noticeable change in medication usage, in 24 hours monitoring 
among patients with asthma and COPD, in contrast with prior results obtained16. 
There were significant decreases in pulmonary function in asthma patients, particularly 
in females. These changes were of less than 100 ml, which were not noticed as changes 
in symptoms by the patients. In the COPD patients there was a reduction in FEV1, FVC 
and PEFR but it was not statistically significant.   
These small changes in both diseases are of particular interest because while not of 
immediate clinical significance they are enough to raise the possibility of small losses of 
lung function which may become cumulative with continuing, or even if intermittent, 
exposure. This was a once off short exposure and it can be envisaged that repeated and 
or prolonged exposure to SHS might produce cumulative damage in these and other lung 
function measurements. Previous studies have shown that airway oxidative stress  
remains increased after the exposure to SHS, representing a possible mechanism for the 
persistence of the deleterious effects of SHS after the end of the exposure17. 
Patients with asthma, not unexpectedly, were more sensitive to the effects of exposure 
but likewise may be more reversible. The long-term consequences may be more serious 
for COPD patients where changes may be more permanent and progressive18. Serial self-
monitoring may be possible for such patients and be more definite but even with this short 
intervention it would appear reasonable to caution patients with these diseases to avoid 
such exposure. 
Some of the strengths of this research include the real-world conditions of SHS 
exposure19, and an identical protocol applied in the three countries with quite different 
climates and smoking behaviours. However, a number of limitations must be considered. 
Changes in forced spirometry were performed the next day, so acute, immediate effects 
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of SHS exposure in FEV1, FVC or in PEFR could not be assessed. Nor were serial 
measurements made to determine the time course of the response and whether there was 
any continuing loss which may contribute to a gradual decline in lung function; this may 
be the case particularly in COPD patients. It was not considered reasonable or feasible to 
undertake forced spirometry in outdoor areas in the frame of this study. We initially 
considered to have a more extensive battery of lung tests, up to pletismography. However, 
for practicality reasons, measuring mid-expiratory flows, inspiratory capacity, and other 
lung parameters, required further standardisation of spirometers and staff, that added time 
and complexity to our simple study design. But, they all should be considered areas for 
future research. With 60 respiratory patients, we must admit our sample size is relatively 
modest, given a reduced budget and limited availability of monitoring devices in each 
country, which were sterilised, reset and reused. No a priori formal sample size was 
estimated, and we think inappropriate to calculate any posterior power calculation, as 
there are many outputs and secondary analyses of interest. However, our findings should 
be considered as proof of concept of larger, more ambitious studies on the unaccounted 
tobacco-related hazards suffered by our asthma and COPD patients. 
 
New research should explore the long-term effects of exposure to SHS in outside areas in 
the respiratory health of asthma and COPD patients. Continuous monitoring of lung 
function (with home, portable spirometers20) and of respiratory symptoms and other 
biosensors. This could be coupled with more accurate and continuous environmental 
assessment of particles and nicotine in the air. These studies, however, will deal with the 
challenge to differentiate exposure to SHS from tobacco, environmental pollution and 
also exposure to SHA. Hence, the effects of SHA in patients with respiratory diseases 
such as asthma and COPD needs further research. In our study, most patients (83.3%) 
were not exposed to electronic cigarettes precluding an assessment.  
 
We conclude that acute, short-term SHS exposure among patients with asthma and COPD 
modifies spirometric indices and is a hazard for patients with these diseases, but did not 
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Age (years) 46.9 (18.7) 63.3 (10.2) 55.1(17.1) 
Weight (Kg) 75.6 (18.1) 80.3(16.5) 78 (17.3) 
Sex 
Male 11 (36.7%) 14 (46.7%) 25 (41.7%) 
Female  19 (63.3%) 16 (53.3%) 35 (58.3%) 
Smoking status 
Current-smoker 8 (26.7%) 21 (70%) 29 (48.3%) 
Ex-smoker 6 (20.0%) 9 (30.0%) 15 (25.0%) 
Never-smoker 16 (53.3%) 0 (0%) 16 (26.7%) 
Lives with a smoker 
Yes 7 (23.3%) 10 (33.3%) 17 (28.3%) 
No 23 (76.7%) 20 (66.7%) 43 (71.7%) 
ACT score 21.8 (3.6) - - 
CAT score - 11.6 (7.5) - 
Number of smokers present in the outdoor smoking area during patient visit 
1-5  22 (73.3%) 22 (73.3%) 44 (73.3%) 
More than 5  8 (26.7%) 8 (26.7%) 16 (26.7%) 
Any unscheduled doctor visit 
Yes 0 (0%) 0 (0%) 0 (0%) 
No 30 (100%) 30 (100%) 60 (100%) 
 
Table 1 footnote: Mean (SD)/n (%); COPD: Chronic Obstructive Pulmonary Disease; 
ACT: Asthma Control Test, with range from 5 to 25; CAT: COPD Assessment Test, 
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Table 2. Symptom questionnaires by diagnosis and sex 
 





p - value 
ACT 
Mean (SD) range 
21.7 (3.5) 
[14 – 25] 
22.0 (4.0) 
[11 - 23] 
0.813 
    





p - value 
CAT 
Mean (SD) range 
11.2  (5.8) 
[2 - 23] 
12.1 (9.2) 
[3 - 37] 
0.770 
 
Table 2 footnote: ACT: Asthma Control Test, with range from 5 to 25; CAT: COPD 








Table 3. Comparison of Forced Expiratory Volume (FEV1), Forced Vital Capacity 
(FVC) and Peak Expiratory Flow Rate (PEFR) before and after SHS Exposure by 
Gender and Disease  
 
FEV1(litres in 1st second) 
Asthma  
 Baseline FEV1  
Mean (SD) 








3.01 (1.05) 2.97 (1.10) 0.03 (-0.04, 0.11) 0.99 (29) 0.33 
Male (n=11) 3.72 (1.12) 3.78 (1.19) -0.06 (-0.23, -
0.09) 
-0.86 (10) 0.41 
Female (n=19) 2.59 (0.76) 2.50 (0.74) 0.09 (0.01, 0.17) 2.50 (180 0.02 
COPD  
 Baseline FEV1  
Mean (SD) 








1.80 (0.56) 1.77 (0.54) 0.03 (-0.03, 0.09) 1.00 (29) 0.33 
Male (n=14) 1.98 (0.53) 1.97 (1.72) 0.01 (-0.10, 0.13) 0.25 (14) 0.81 
Female (n=16) 1.61 (0.55) 1.56 (0.56) 0.05 (-0.02, 0.12) 1.54 (14) 0.15 
FVC (litres) 
Asthma  
 Baseline FVC  
Mean (SD) lts 
Post Exposure FVC. 







3.97 (1.33) 3.89 (1.37) 0.07 (0.00, 0.15) 2.30 (29) 0.02 
Male (n=11) 5.10 (1.29) 5.05 (1.37) 0.19 (-0.07, 0.18) 0.91 (10) 0.38 
Female (n=19) 3.32 (0.84) 3.22 (0.19) 0.10 (0.00-0.90) 2.15 (18) 0.04 
COPD  
 Baseline FVC  
Mean (SD) lts 
Post Exposure FVC. 





All COPD  
(n= 30) 
2.90 (0.81) 2.87 (0.77) 0.03 (-0.07, 0.12) 0.62 (29) 0.54 
Male (n=14) 3.26 (0.79) 3.27 (0.67) -0.00 (-0.16, 0.16) -0.01 (14) 0.99 
Female (n=16) 2.55 (0.69) 2.49 (0.22) 0.06 (-0.06, 0.18) 1.03 (14) 0.32 
PEFR (litres per min)  
Asthma  
 Baseline PEFR  
Mean (SD) l/min 
Post Exposure PEFR. 







434 (211) 426 (223) 8.59 (-13.84, 
31.03) 
0.78 (29) 0.43 
Male (n=11) 568 (199) 584 (240) -16.82 (-66.76-
33.13) 
-0.75 (10) 0.5 
Female (n=19) 357 (181) 334 (155) 23.31 (1.09, 
45.52) 
2.20 (18) 0.04 
COPD  
 Baseline PEFR  
Mean (SD)l/min 








343 (183) 328 (151) 14.27 (-16.83, 
45.37) 
0.94 (27) 0.35 
Male (n=14) 377 (212) 345 (174) 31.77 (-21.60, 
85.14) 
1.30 (12) 0.22 
Female (n=16) 312 (154) 313 (132) -0.89 (-40.78, 
38.99) 
-0.04 (14) 0.96 
 
Table 3 footnote: COPD: Chronic Obstructive Pulmonary Disease; * Student´s t-test 
(degrees of freedom); 95% CI: 95% Confidence Interval 
 
 
 
 
 
 
 
  
  
